HAMLET TO4 B — HAMLET Pharma AB Income Statement
0.000.00%
Last trade - 00:00- SEK261.96m
- SEK222.34m
Annual income statement for HAMLET Pharma AB, fiscal year end - June 30th, SEK millions except per share, conversion factor applied.
2018 June 30th | 2019 June 30th | 2020 June 30th | 2021 June 30th | 2022 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | SAS | SAS | SAS | SAS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 16.3 | 17.1 | 23.4 | 7.5 | 17.1 |
| Operating Profit | -16.3 | -17.1 | -23.4 | -7.5 | -17.1 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -16.3 | -17.1 | -23.4 | -7.72 | -17.2 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -16.3 | -17.1 | -23.4 | -7.72 | -17.2 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -16.3 | -17.1 | -23.4 | -7.72 | -17.2 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -16.3 | -17.1 | -23.4 | -7.72 | -17.2 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.175 | -0.178 | -0.229 | -0.075 | -0.156 |
| Dividends per Share |